Wolters Kluwer to acquire AgileMD for up to $100 million

By Public Technologies
  • Wolters Kluwer Health has agreed to acquire AI-powered clinical decision support provider AgileMD for up to $100 million.
  • Terms include a $40 million upfront payment, with the balance contingent on performance targets.
  • The acquisition will expand UpToDate into embedded clinical workflows and local guidelines.
  • AgileMD expects $7 million in annual recurring revenue by year-end 2026; closing is expected in the first quarter of 2027 or sooner.
  • The deal targets a return on invested capital of at least 8% within 3-5 years, with an immaterial impact on adjusted earnings.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Wolters Kluwer NV published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611131200PRIMZONEFULLFEED1001303544) on November 13, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.